Overview

A Study to Assess Bioequivalence of Fezolinetant Formulations in Healthy Female Participants

Status:
Completed
Trial end date:
2021-02-26
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the bioequivalence of a single dose of fezolinetant test formulation compared to a single dose of fezolinetant reference formulation under fasting conditions. This study will also evaluate the safety and tolerability of a single dose of fezolinetant test formulation and a single dose of fezolinetant reference formulation.
Phase:
Phase 1
Details
Lead Sponsor:
Astellas Pharma Global Development, Inc.